Caradigm USA LLC v. Pruithealth, Inc.

964 F.3d 1259
CourtCourt of Appeals for the Eleventh Circuit
DecidedJuly 10, 2020
Docket19-11648
StatusPublished
Cited by10 cases

This text of 964 F.3d 1259 (Caradigm USA LLC v. Pruithealth, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Caradigm USA LLC v. Pruithealth, Inc., 964 F.3d 1259 (11th Cir. 2020).

Opinion

Case: 19-11648 Date Filed: 07/10/2020 Page: 1 of 49

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT ________________________

No. 19-11648 ________________________

D.C. Docket No. 1:15-cv-02504-SCJ

CARADIGM USA LLC,

Plaintiff - Appellee,

versus

PRUITTHEALTH, INC., formerly known as UHS-Pruitt Corp.,

Defendant - Appellant.

________________________

Appeal from the United States District Court for the Northern District of Georgia ________________________

(July 10, 2020) Case: 19-11648 Date Filed: 07/10/2020 Page: 2 of 49

Before MARTIN, NEWSOM, and O’SCANNLAIN,* Circuit Judges.

NEWSOM, Circuit Judge:

This is the story of a deal gone south. PruittHealth, Inc., a healthcare

provider, was looking for a new way to organize its patient data; Caradigm USA

LLC is in the business of delivering software solutions to healthcare providers.

The companies executed a contract pursuant to which Pruitt would pay Caradigm

to pull patient information from Pruitt’s various systems and organize it so that

each patient’s medical and billing records would be available in one place.

But alas. A little more than six months in, Pruitt grew dissatisfied with

Caradigm’s progress and announced that it was walking away from the project.

Caradigm informed Pruitt that it stood ready to perform and warned Pruitt that it

couldn’t just unilaterally ditch the contract. Pruitt didn’t respond, and Caradigm

eventually sued. The district court decided on summary judgment that Pruitt had

anticipatorily breached the contract and that Caradigm was therefore entitled to the

full value of the deal. Because that value was uncertain, the district court left the

issue of damages for trial. After a four-day trial, a jury awarded Caradigm $11

million, which included contract damages, compound interest on those damages,

and attorney’s fees and expenses.

* Honorable Diarmuid F. O’Scannlain, United States Circuit Judge for the Ninth Circuit, sitting by designation.

2 Case: 19-11648 Date Filed: 07/10/2020 Page: 3 of 49

On appeal, Pruitt doesn’t contest the district court’s determination that it

breached, but it does contend that the district court erred in numerous ways leading

up to the jury’s verdict, which, it says, resulted in an overstated damages award

and erroneous awards of interest and fees. We conclude that the district court did

not reversibly err in most of the ways that Pruitt claims, and we will therefore

affirm the awards of contract damages and fees, as well as the determination that

Caradigm is entitled to recover interest on the damages award. Because we hold

that it was error to compound the interest, however, we will vacate that award and

remand for the district court to calculate interest in simple terms.

I

A

PruittHealth, Inc. is a private, for-profit healthcare provider dealing mostly

in home healthcare, skilled-nursing facilities, and hospices. Pruitt was looking for

a new way to store its patient records, which were located across multiple systems

and difficult to access for billing and treatment purposes. Caradigm USA LLC is a

software company that services healthcare providers. As relevant here, Pruitt was

particularly interested in one service that Caradigm offered—the “Amalga

Platform”—which could aggregate patients’ clinical and financial information.

Pruitt and Caradigm executed an agreement pursuant to which Caradigm

would pull patient information from Pruitt’s separate data systems and aggregate it

3 Case: 19-11648 Date Filed: 07/10/2020 Page: 4 of 49

so that each patient’s medical and billing records would be accessible in a single

platform. The contract provided the legal framework for the agreement, defined

important terms, included an order form showing the goods and services that Pruitt

purchased, and explained the details of how the parties would implement

Caradigm’s software. 1 The contract also contemplated a crucial turning point—

“First Productive Use”—when Pruitt would initially employ Caradigm’s software

“to process actual patient data in a live production environment.”

After First Productive Use—and this is important to the damages dispute

before us—the contract provided for a significant increase in monthly payments.

The order form specified that Pruitt’s subscription to the Amalga Platform would

cost $64,649 per month, based on “[m]edium” usage, with payments “starting on

First Productive Use.” 2 Pruitt’s medium subscription size was calculated based on

three metrics: the number of data feeds (i.e., inbound electronic data from Pruitt’s

information systems), the number of messages (i.e., transmission of certain files)

per day, and the number of permitted users. So, the more feeds, messages, and

users, the bigger the platform size that Pruitt would need (and vice versa). The

1 The parties refer to the three parts of the agreement as the “Order Form,” the “Cloud Services Agreement,” and the “Statement of Work.” We will simply refer to the three parts collectively as “the contract” or “the agreement.” 2 It also stated that Pruitt would pay $4,000 per month for a “Pre-First Productive Use Hosting Fee” (beginning from the project’s “kick-off” and continuing until First Productive Use), $20,000 per month for an Amalga Development License (beginning when the contract took effect), and other costs for services provided by Caradigm.

4 Case: 19-11648 Date Filed: 07/10/2020 Page: 5 of 49

agreement stated that each quarter, “Caradigm w[ould] review [Pruitt’s] actual

usage” against the capacity level for its then-current platform size, and “[i]f each

metric f[ell] below its threshold for a lower [platform] size, then [Pruitt] w[ould]

be moved down” a size and charged fees for that smaller size the next quarter. The

agreement also provided for the opposite: If any metric was exceeded in a quarter,

Pruitt would be moved up a platform size. By its terms, the agreement was set to

“run for an Initial Term ending five years after the date of First Productive Use.”

But the project never reached First Productive Use. An early step in the

implementation of Caradigm’s software called for Pruitt to send Caradigm a data

sample so that Caradigm could test its ability to match patient files coming from

disparate sources (i.e., the “patient matching” process). Pruitt was apparently

disappointed with the results of an initial patient-matching test in December 2014.

Caradigm’s internal communications show that, as of January 23, 2015, it planned

to offer Pruitt two options with regard to patient matching: Pruitt could either (1)

continue with Caradigm’s “basic patient matching as described in the proposal,”

which “include[d] basic support (in house, no third party),” with any

“[e]nhancements” and additional services to be billed separately, or (2) purchase a

third-party matching system, which had more “bells and whistles.”

Caradigm was never able to present those options to Pruitt. On January 29,

Pruitt’s Chief Information Officer, Dan Martin, telephoned Caradigm account

5 Case: 19-11648 Date Filed: 07/10/2020 Page: 6 of 49

executive Tina Mirkheshti to notify her that Pruitt was likely to abandon the

project. Less than a month later—on February 17—Pruitt sent Caradigm a

confirmatory email stating, in relevant part:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
964 F.3d 1259, Counsel Stack Legal Research, https://law.counselstack.com/opinion/caradigm-usa-llc-v-pruithealth-inc-ca11-2020.